ATAI - atai schizophrenia candidate shows promise with interim phase 2a data

atai Life Sciences' (ATAI +0.4%) RL-007 for cognitive impairment associated with schizophrenia demonstrated potential pro-cognitive effects in a cohort in a phase 2a study. As a result, atai will commit additional funding to the program to accelerate clinical development. In addition, there were encouraging assessments for the 8-patient cohort based on two quantitative biomarkers, qEEG (quantitative electroencephalogram) and ERP (evoked-response potential), as well as changes that are consistent with improved cognition. Full results are expected by the end of the year. Read about a trial atai is conducting for a form of ketamine for treatment-resistant depression.

For further details see:

atai schizophrenia candidate shows promise with interim phase 2a data